寶馨科技(002514.SZ):擬將蘇州寶馨註冊資本增加至1.5億元
格隆匯6月4日丨寶馨科技(002514.SZ)公佈,公司於2021年6月4日召開第五屆董事會第六次會議和第五屆監事會第五次會議,審議通過了《關於全資子公司增加註冊資本的議案》,董事會同意公司以自有或自籌資金人民幣12102.262505萬元對全資子公司蘇州寶馨智能裝備有限公司(原蘇州艾諾鎂科技有限公司,“蘇州寶馨”)進行增資。為進一步落實公司及子公司的發展規劃,支持產業持續發展,公司擬將蘇州寶馨註冊資本由人民幣2897.737495萬元整增加至15000萬元整,此次增資完成後,公司仍持有蘇州寶馨100%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.